Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD) to improve patients’ quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Our immediate goal is to develop a peptide-based compound, CT-526, for FTD.